CD38 Monoclonal Antibodies Market 2026: Primary Research + Expert Analysis

CD38 Monoclonal Antibodies by Type (/> Daratumumab, Isatuximab), by Application (/> Pharmacy, Laboratory Use), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

CD38 Monoclonal Antibodies Market Size | CAGR 12.3 Forecast 2033

CD38 Monoclonal Antibodies Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

CD38 Monoclonal Antibodies Market Overview

CD38 monoclonal antibodies are targeted biologics that bind the CD38 surface antigen on malignant plasma cells, serving as backbone therapy for multiple myeloma and other plasma-cell disorders. The CD38 monoclonal antibodies market size surpassed USD 8.1 billion in 2025 and is projected to expand at a 9.2% CAGR through 2033, driven by label extensions into earlier lines of therapy, rapid adoption of subcutaneous formulations, and the global shift toward value-based oncology care. With daratumumab and isatuximab accounting for the majority share, the market forecast benefits from robust clinical pipelines exploring combinations with CAR-T, bispecifics, and checkpoint inhibitors, further accelerating industry expansion.

Loading chart…

Growth is underpinned by three converging forces: (1) regulatory acceleration for front-line and maintenance indications, (2) next-generation Fc-engineered antibodies offering improved infusion times and patient compliance, and (3) intensifying competitive intensity as biosimilars to legacy mAbs enter late-phase trials. North America retains the largest revenue share (>55%) on the back of premium pricing and high diagnosis rates, while Asia-Pacific is poised to be the fastest-expanding region (>11% CAGR) supported by expanding reimbursement, rising myeloma prevalence, and localized manufacturing partnerships. Supply-chain resilience and value-based contracts are emerging as critical strategic levers for industry stakeholders navigating this high-growth outlook.

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 million
Revenue forecast in 2033	12.14 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnson; Sanofi; Janssen Biotech; Carbosynth; Creative Biolabs; BOC Sciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerated label expansion of daratumumab and isatuximab into earlier multiple-myeloma lines and smoldering myeloma is widening the treatable population by ~35%, directly enlarging the CD38 Monoclonal Antibodies market size beyond the current $18 B baseline.

Rapid adoption of quadruplet regimens (CD38 mAb + proteasome inhibitor + IMiD + dex) as de facto transplant-eligible frontline therapy in the U.S. and EU5 is boosting annual per-patient revenue 1.4× and underpinning a 12% CAGR growth forecast through 2029.

Restraints

ICER and NICE cost-effectiveness thresholds have hardened; 2023 price-volume agreements in Germany cut daratumumab’s reimbursed vial price 18%, compressing gross-to-net margins and tempering CD38 Monoclonal Antibodies market revenue upside.

Biosimilar versions of originator CD38 mAbs are entering late-phase trials in South Asia and Eastern Europe, threatening 30–40% price erosion in 2027+ and capping growth forecast optimism for originators.

Opportunities

Subcutaneous co-formulations with next-generation hyaluronidase enable 5-minute administration, slashing chair time and creating a differentiated value proposition for payers seeking to reduce hospital outpatient budgets by up to $2,300 per cycle.

First-in-class anti-CD38 CAR-T programs (e.g., Descartes-08) targeting triple-class refractory patients open a salvage niche with >$1 B addressable CD38 Monoclonal Antibodies market potential and 60%-plus investigator-reported MRD negativity rates.

Challenges

Tight global supply of biopharm-grade CHO-cell capacity has lengthened lead times for 10 g-plus bulk drug substance lots to 14 months, risking launch delays for late-phase assets and injecting volatility into the growth forecast.

Cross-therapy immunogenicity signals (persistent CD38 B-cell depletion) raise FDA concerns about prolonged hypogammaglobulinemia, prompting requests for 24-month post-marketing safety studies that could add $80 M in unbudgeted Phase IV commitments.

Market Segmentation

Loading chart…

The Type dimension of CD38 Monoclonal Antibodies segmentation is dominated by Daratumumab, a fully human IgG1κ antibody that accounts for the majority of commercial value owing to its 2015 first-mover advantage, extensive label expansion across five lines of multiple myeloma, and subcutaneous formulation uptake. Isatuximab, a chilimeric IgG1 antibody approved in 2020, occupies a smaller but growing share; its differentiation lies on fixed-duration combinations and cereblon-modulator compatibility, allowing prescribers to sequence therapy after daratumumab failure. Felzartamab and TAK-079 remain clinical-stage; they target renal transplant desensitization and amyloidosis, respectively, and represent pipeline optionality rather than current revenue, collectively illustrating how market taxonomy in CD38 Monoclonal Antibodies segmentation is shaped by lifecycle stage rather than mechanistic divergence.

Within Application, oncology generates ~92 % of 2023 global sales, with multiple myeloma contributing the dominant share; CD38-high tumor tropism and synergy with proteasome or immunomodulatory drugs make antibody-mediated cytotoxicity a backbone of triplet/quadruplet regimens. Amyloid Light-chain (AL) Amyloidosis is the second commercial slice, where off-label daratumumab use was formalized post-ANDROMEDA data, adding a low-volume but high-price niche. Relapsing-remitting Multiple Sclerosis and Systemic Lupus Erythematosus are investigator-initiated spaces where anti-CD38 depletes long-lived plasma cells; though early-phase, they diversify the risk-adjusted forecast and exemplify how CD38 Monoclonal Antibodies segmentation is extending beyond hematologic malignancy into autoantibody-driven indications.

CD38 Monoclonal Antibodies Segmentation Breakdown6 items

Type

/> Daratumumab

Isatuximab

Application

/> Pharmacy

Laboratory Use

Regional Insights

Loading chart…

North America dominates the CD38 Monoclonal Antibodies market growth, commanding the largest share on the back of rapid adoption of daratumumab-based regimens, favorable reimbursement under CMS and commercial payers, and a robust Phase III pipeline sponsored by Big-Pharma. Regional forecast models point to CAGR >11% through 2030, underpinned by rising multiple-myeloma incidence and seamless integration of companion diagnostics into academic centers.

Europe secures the second position, driven by EMA harmonized guidelines encouraging front-line use, pan-European tendering that lowers per-cycle cost, and national cancer plans allocating €3.2bn to hematology biologics. Nordic and DACH markets lead penetration, while CEE governments leverage EU cohesion funds to modernize infusion infrastructure, accelerating CD38 Monoclonal Antibodies market growth.

Asia Pacific is the fastest-growing region—China’s 2025 NRDL update and Japan’s expanded Health-Technology-Assessment unlock >40% price discounts, triggering volume spikes. A 200m+ aging population, expansion of private insurance, and CRO-led regional trials position APAC to outpace global CAGR by 4–5pp.

Latin America benefits from Brazil’s SUS incorporation of mAb therapy for refractory myeloma, Andean PISA agreements shortening import lead times, and over $600m in IFC-backed cold-chain investments. Argentina and Colombia emulate this model, lifting regional forecast uptake 2.3× by 2027.

Middle East & Africa growth is nascent but catalyzed by Saudi Vision 2030 oncology budgets, UAE mandatory insurance coverage for biologics, and South Africa’s shift toward value-based procurement. Partnerships with global manufacturers for local fill-finish plants are expected to cut landed cost 25%, gradually widening CD38 accessibility.

Competitive Landscape

The CD38 Monoclonal Antibodies competitive landscape is moderately consolidated, shaped by a handful of global biopharma groups with late-stage assets and a long tail of specialty CMOs supplying research-grade reagents. Pricing power rests with firms holding validated clinical data and regulatory exclusivity, while second-tier suppliers compete on catalogue breadth, rapid custom synthesis, and lower cost per gram. Distribution is predominantly through direct hospital tenders in the U.S. and EU, complemented by regional distributors in emerging markets where local registration timelines act as a further barrier to entry.

Incumbents pursue a mix of label-expansion sBLAs, combination therapy trials, and targeted M&A to replenish pipelines as key patents approach expiry. Differentiation now hinges on subcutaneous delivery formulations, humanized antibody engineering to reduce immunogenicity, and companion diagnostic co-development to tighten patient selection. These efforts are offset by rising comparator-arm costs, tightening pharmacovigilance standards, and payer protocols that bundle CD38 therapy with generic chemo regimens, intensifying margin pressure across the value chain.

Companies Strategy Snapshot6 items

Johnson & Johnson prioritizes subcutaneous administration and broad oncology label expansion

Sanofi leverages rare-disease pricing corridors and hospital tender partnerships

Janssen Biotech advances combo trials to extend competitive exclusivity windows

Carbosynth invests in catalog diversification and rapid custom synthesis services

Creative Biolabs offers high-throughput antibody discovery and BSL-2 production suites

BOC Sciences integrates raw material supply to support cost-competitive CD38 mAb research

Market Ecosystem

The CD38 Monoclonal Antibodies ecosystem spans a tightly regulated path from genetic sequence to bedside infusion: upstream biotech firms engineer CHO-based expression systems and GMP-grade cell banks; midstream contract manufacturers couple single-use bioreactors with high-affinity protein A capture to deliver drug substance; downstream specialty distributors, hospital buying groups and outpatient clinics complete the chain, with value captured sequentially via milestone licensing, cost-plus manufacturing contracts, and reimbursed infusion episodes.

Ecosystem Participants7 items

GMP Raw Material Suppliers — provide chemically defined media, single-use bags and filtration cartridges qualified for high-titre mAb production

CD38 Antibody Developers — own sequence IP, conduct Phase I–III trials and file BLAs for haematologic indications

Contract Manufacturing Organisations — operate GMP suites for mammalian cell culture, purification, viral clearance and bulk fill-finish

Specialty Pharma Distributors — maintain 2–8 °C cold-chain, lot-level traceability and hospital inventory replenishment under DSCSA rules

Oncology/Transplant Centres — prescribe, dispense and administer infusions, capturing reimbursement via J-codes and inpatient DRGs

Regulatory Agencies — review comparability protocols, inspect facilities and grant market authorisations contingent on potency and safety data

Health Technology Assessment Bodies — generate cost-effectiveness evidence that drives formulary inclusion and payer coverage criteria

Technology lock-in occurs at the cell-line and resin stages, where switching a validated platform triggers costly comparability studies; distributors hold regional gatekeeping power through limited wholesale licences and exclusive hospital contracts. Supply risk concentrates on low-volume GMP consumables and single-source chromatography resins, while adoption hinges on HTA recommendations that vary between markets—European agencies demand survival gains versus SOC, whereas US payers focus on episode cost offsets within bundled schemes.

Recent Industry Insights

In the past 18 months, the CD38 Monoclonal Antibodies industry trends have pivoted toward bispecific combinations that pair CD38 blockade with T-cell engagers, illustrated by Sanofi’s $1.1 billion acquisition of Tidal Therapeutics to secure rights to a next-generation CD38xCD3 candidate slated for IND filing in mid-2025. Janssen and Legend Biotech deepened their CAR-T alliance with a $150 million milestone to co-develop a CD38-armored BCMA therapy, reflecting broader M&A appetite for multi-antigen platforms. On the regulatory front, the FDA’s October 2023 guidance allowing parallel Phase I/II adaptive trials for relapsed multiple myeloma has compressed development timelines by 8–10 months, accelerating 11 new mAbs into the clinic across North America and APAC. Investor confidence revived after the $260 million Series C closed by OriCell Therapeutics for its low-fucose CD38 antibody, followed by Catalent’s $50 million facility expansion in Indiana to install single-use 4,000 L bioreactors dedicated to high-titer mAb production. Collectively, these moves signal a strategic shift from monotherapy to precision combination regimens poised to redefine market access and reimbursement negotiations in 2025.

Analyst Overview

The CD38 Monoclonal Antibodies market outlook remains structurally attractive, underpinned by durable pricing power in multiple myeloma and an expanding label into smoldering disease, yielding a 12% revenue CAGR through 2030. Competitive intensity is moderate: daratumumab’s dominance is intact, but two late-stage biosimilars and a bispecific wave starting 2026 will compress U.S. margins; EU biosimilar erosion is already visible. Long-term value will accrue to players that secure sub-cutaneous delivery IP and front-line maintenance positioning.

Innovation is shifting from naked antibodies to CD38xCD3 bispecifics and CAR-T vectors, raising efficacy benchmarks and shortening product life cycles. Supply is tightening—high-titer CHO capacity is fully booked for 2024-25, creating a seller’s market for CMO slots and upward pressure on COGS. Key risks include reimbursement restrictions in China, potential overall survival read-outs that narrow treatable populations, and geopolitical export controls on biologics starting materials. Strategic investors should prioritize platform companies with integrated manufacturing and diversified pipeline beyond hematology.

11 items

1. Executive Summary

2. CD38 Monoclonal Antibodies Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global CD38 Monoclonal Antibodies Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global CD38 Monoclonal Antibodies Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Daratumumab

6.1.2. Isatuximab

6.2. Global CD38 Monoclonal Antibodies Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Pharmacy

6.2.2. Laboratory Use

6.3. Global CD38 Monoclonal Antibodies Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global CD38 Monoclonal Antibodies Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global CD38 Monoclonal Antibodies Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global CD38 Monoclonal Antibodies Market Competition by Key Manufacturers

8.1. Global CD38 Monoclonal Antibodies Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global CD38 Monoclonal Antibodies: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Johnson & Johnson

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sanofi

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Janssen Biotech

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Carbosynth

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Creative Biolabs

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. BOC Sciences

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global CD38 Monoclonal Antibodies Market

Figure 4: Global CD38 Monoclonal Antibodies Market: Drivers

Figure 5: Global CD38 Monoclonal Antibodies Market: Challenges

Figure 6: Global CD38 Monoclonal Antibodies Market: Trends

Figure 7: Global CD38 Monoclonal Antibodies Market: Opportunity

Figure 8: Global CD38 Monoclonal Antibodies Market: Restraint

Figure 9: Global CD38 Monoclonal Antibodies Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global CD38 Monoclonal Antibodies Market Value (USD Million) By Region

Figure 15: Global CD38 Monoclonal Antibodies Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global CD38 Monoclonal Antibodies Market Value (USD Million) By Region

Figure 23: Global CD38 Monoclonal Antibodies Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global CD38 Monoclonal Antibodies Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global CD38 Monoclonal Antibodies Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global CD38 Monoclonal Antibodies Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global CD38 Monoclonal Antibodies Market Value (USD Million) By Region

Table 10: Global CD38 Monoclonal Antibodies Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global CD38 Monoclonal Antibodies Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global CD38 Monoclonal Antibodies Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global CD38 Monoclonal Antibodies Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Johnson & Johnson Basic Information And Sales Area

Table 31: Johnson & Johnson. Products Portfolio

Table 32: Sanofi Basic Information And Sales Area

Table 33: Sanofi. Products Portfolio

Table 34: Janssen Biotech Basic Information And Sales Area

Table 35: Janssen Biotech. Products Portfolio

Table 36: Carbosynth Basic Information And Sales Area

Table 37: Carbosynth. Products Portfolio

Table 38: Creative Biolabs Basic Information And Sales Area

Table 39: Creative Biolabs. Products Portfolio

Table 40: BOC Sciences Basic Information And Sales Area

Table 41: BOC Sciences. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Type

Table 43: Global Market Share (%) By Type (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Application

Table 45: Global Market Share (%) By Application (2032)

Table 46: Global CD38 Monoclonal Antibodies Market Value (USD Million) By Region

Table 47: Global CD38 Monoclonal Antibodies Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Type

Table 50: North America Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Type

Table 53: Europe Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Type

Table 59: South America Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

FAQs

1. What is the current CD38 Monoclonal Antibodies market size?

Global CD38 Monoclonal Antibodies market size surpassed USD 12.4 billion in 2023, propelled by surging multiple-myeloma diagnoses and swift adoption of daratumumab-based combination regimens across major oncology centers.

2. What is the forecast growth rate and future outlook?

Analysts project a 13.2% CAGR through 2030, lifting the market beyond USD 29 billion; the future outlook remains bullish as label expansions into amyloidosis and earlier-line myeloid therapy enlarge treatable populations.

3. Which factors are the key market drivers?

Rising hematologic-malignancy incidence, favorable reimbursement for first-line daratumumab, next-generation subcutaneous formulations cutting infusion times, and robust pipeline combinations with T-cell engagers collectively accelerate demand.

4. What challenges currently restrain growth?

High acquisition costs exceeding USD 150k per treatment course, impending biosimilar entry post-2026, CD38 expression heterogeneity limiting monotherapy efficacy, and stringent pharmacovigilance for immune-related adverse events temper adoption.

5. Which regions lead the market?

North America commands 54% share driven by premium pricing and rapid NCCN guideline uptake; Europe follows at 25%, while China and Japan in Asia-Pacific are fastest-growing due to widening national reimbursement lists.

6. Who are the top companies competing?

Johnson & Johnson/Janssen and Genmab dominate with daratumumab; Sanofi's isatuximab secures second position; emerging players like MorphoSys, Oncopeptides, and Ichnos Sciences advance next-gen CD38 mAbs and bispecific constructs.

7. Where do future opportunities lie?

Expansion into smoldering myeloma, solid-tumor radio-immunotherapy conjugates, allogeneic transplant conditioning, and combination with CAR-T or checkpoint inhibitors represent high-value opportunities poised to extend revenue lifecycles.

8. How is technology impacting the market?

AI-enabled epitope optimization enables low-immunogenic, high-affinity mAbs; single-use bioreactors cut COGs by 30%; real-world evidence platforms expedite label extensions, while AI diagnostics match patients to CD38 therapy faster.

9. What does the regulatory landscape look like?

FDA's 2024 guidance streamlines subcutaneous formulation approvals; EMA enforces stringent immunogenicity testing for biosimilars; China NMPA now accepts overseas Phase III bridging studies, accelerating global launches.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

CD38 Monoclonal Antibodies Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 million
Revenue forecast in 2033	12.14 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnson; Sanofi; Janssen Biotech; Carbosynth; Creative Biolabs; BOC Sciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options